Oasmia’s Lead Cancer Product Paclical® Receives Market Approval in the Russian Federation

UPPSALA, Sweden, Apr. 20 (Korea Bizwire) — Paclical, a novel formulation of paclitaxel based on Oasmia’s XR-17 technology, was approved for treatment of (i.e., it received market authorization for) epithelial ovarian cancer in combination with carboplatin. XR-17 is non-toxic and forms water soluble nanoparticles with paclitaxel. “After many years of significant efforts by everyone involved [...]